
IQVIA Hlds (IQV) Stock Forecast & Price Target
IQVIA Hlds (IQV) Analyst Ratings
Bulls say
IQVIA Holdings is experiencing robust growth across several segments, with notable increases in FSP, RWE, and CSMS in Q3, indicating strong year-over-year performance. The company is benefiting from improved decision-making timelines and a solid pipeline in its commercial operations, driven by recent drug launches, which has contributed to an increase in RFP flow and a significant improvement in its win rate. Furthermore, IQVIA projects a growth rate of over 4% for its R&D Services on a constant currency basis, supported by a favorable pricing environment that has enabled the company to be selective in deal-making.
Bears say
The financial analysis of IQVIA Holdings reveals several fundamental concerns contributing to a negative outlook on the stock. Firstly, the year-over-year constant currency growth has significantly declined to 3.8%, down from 6.8% in the previous quarter, indicating a weakening growth trajectory amidst challenging comparisons from the prior year. Additionally, investor apprehensions regarding potential revenue growth slowdowns in 2026 are compounded by IQV's admission that rising interest rates may exert further pressure on margins and earnings, suggesting vulnerabilities in their financial stability moving forward.
This aggregate rating is based on analysts' research of IQVIA Hlds and is not a guaranteed prediction by Public.com or investment advice.
IQVIA Hlds (IQV) Analyst Forecast & Price Prediction
Start investing in IQVIA Hlds (IQV)
Order type
Buy in
Order amount
Est. shares
0 shares